AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Nano Research Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article

Glioma cell membrane camouflaged cinobufotalin delivery system for combinatorial orthotopic glioblastoma therapy

Zibin Song1,2,§, Liqian Zhao1,2,§, Weiyi Fang3,§, Siyun Guo4, Anqi Xu4, Zhengming Zhan1,2, Yonghua Cai1,2, ShuaiShuai Xue1,2, Peng Chai1,2, Qiuhua Jiang5( ), Peng Zhao4( ), Ye Song1,2,5( )
Department of Neurosurgery, Southern Medical University Nanfang Hospital, Guangzhou 510515, China
Institute of Brain Diseases, Nanfang Hospital of Southern Medical University, Guangzhou 510515, China
Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China
NMPA Key Laboratory for Research and Evaluation of Drug Metabolism Guangdong, Provincial Key Laboratory of Cardiac Function and Microcirculation Guangdong, Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
Department of Neurosurgery, Ganzhou People's Hospital, Ganzhou 341000, China

§ Zibin Song, Liqian Zhao, and Weiyi Fang contributed equally to this work.

Show Author Information

Graphical Abstract

We construct a biomimetic nanocarrier (Cu2−xSe-CB@MEM, CCM), consisting of Cu2−xSe nanoparticle modified by cinobufotalin (CB), camouflaged with Ln229 membrane. The optimized cinobufotalin based chemotherapy combining with the near-infrared-II (NIR-II) irradiation induces glioblastoma cell cycle arrest and promotes apoptosis.

Abstract

Glioblastoma (GBM) belongs to the deadliest primary malignancies with high mortality rate and poor prognosis. Over the past decades, less progress has been made to treat GBM, owing largely to the lack of effective chemotherapeutics and poor drug accumulation in the glioma tissue. In order to address this issue, we present an efficient biomimetic nanocomposite (Cu2−xSe-CB@MEM, CCM), consisting of Cu2−xSe nanoparticle core modified by cinobufotalin (CB), a toad venom extract, which is camouflaged with glioma cell Ln229 membrane. It is demonstrated that CB can decrease the protein activity of inosine monophosphate dehydrogenase 1 (IMPDH1), a key target correlated with prognosis, through intermolecular hydrogen bonding with amino acid residues ARG-105 and ASP-77. The glioma cell membrane-camouflage endows the CCM with blood-brain barrier penetration and homology tumor-targeted ability. The optimized cinobufotalin based chemotherapy combining with the near-infrared-II (NIR-II) irradiation shows outstanding inhibition effect to glioma cells, by blocking cell cycle and inducing apoptosis. In vivo mice bearing orthotopic Ln229 GBM treated with CCM+NIR-II (CCM+L) have significantly suppressed tumor growth and extended survival, without side effect. The glioma cell membrane camouflaged nanocomposite of Cu2−xSe and cinobufotalin with its significant anti-glioma property and well biosafety will provide novel alternatives for clinical treatment of GBM.

Keywords

glioblastomacinobufotalinbiomimeticsphotothermal therapyblood-brain barrier

Electronic Supplementary Material

Download File(s)
12274_2023_5807_MOESM1_ESM.pdf (1.2 MB)

References

[1]

Ostrom, Q. T.; Patil, N.; Cioffi, G.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J. S. Corrigendum to: CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro-Oncol. 2020, 24, 1214.
Crossref Google Scholar
[2]

Louis, D. N.; Perry, A.; Wesseling, P.; Brat, D. J.; Cree, I. A.; Figarella-Branger, D.; Hawkins, C.; Ng, H. K.; Pfister, S. M.; Reifenberger, G. et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncol. 2021, 23, 1231–1251.
Crossref Google Scholar
[3]

Shergalis, A.; Bankhead III, A.; Luesakul, U.; Muangsin, N.; Neamati, N. Current challenges and opportunities in treating glioblastoma. Pharmacol. Rev. 2018, 70, 412–445.
Crossref Google Scholar
[4]

Horbinski, C.; Berger, T.; Packer, R. J.; Wen, P. Y. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat. Rev. Neurol. 2022, 18, 515–529.
Crossref Google Scholar
[5]

Stupp, R.; Taillibert, S.; Kanner, A.; Read, W.; Steinberg, D.; Lhermitte, B.; Toms, S.; Idbaih, A.; Ahluwalia, M. S.; Fink, K. et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA 2017, 318, 2306–2316.
Crossref Google Scholar
[6]

Li, D. C.; Zhong, X. K.; Zeng, Z. P.; Jiang, J. G.; Li, L.; Zhao, M. M.; Yang, X. Q.; Chen, J.; Zhang, B. S.; Zhao, Q. Z. et al. Application of targeted drug delivery system in Chinese medicine. J. Controlled Release 2009, 138, 103–112.
Crossref Google Scholar
[7]

Zhang, Z. T.; Ji, Y.; Hu, N.; Yu, Q. Q.; Zhang, X. R.; Li, J.; Wu, F. L.; Xu, H. E.; Tang, Q. Y.; Li, X. L. Ferroptosis-induced anticancer effect of resveratrol with a biomimetic nano-delivery system in colorectal cancer treatment. Asian J. Pharm. Sci. 2022, 17, 751–766.
Crossref Google Scholar
[8]

Meng, H. N.; Shen, M. Q.; Li, J. J.; Zhang, R. X.; Li, X.; Zhao, L.; Huang, G.; Liu, J. J. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis. Eur. J. Pharmacol. 2021, 906, 174280.
Crossref Google Scholar
[9]

Hou, R. T.; Li, Y. H.; Luo, X. J.; Zhang, W.; Yang, H. L.; Zhang, Y. W.; Liu, J. H.; Liu, S. H.; Han, S. Y.; Liu, C. et al. ENKUR expression induced by chemically synthesized cinobufotalin suppresses malignant activities of hepatocellular carcinoma by modulating β-catenin/c-Jun/MYH9/USP7/c-Myc axis. Int. J. Biol. Sci. 2022, 18, 2553–2567.
Crossref Google Scholar
[10]

Li, W. Q.; Pei, S. H.; Zhang, X. J.; Qi, D. F.; Zhang, W. K.; Dou, Y. Y.; Yang, R. H.; Yao, X.; Zhang, Z. S.; Xie, S. Q. et al. Cinobufotalin inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells through down-regulate β-catenin in vitro and in vivo. Eur. J. Pharmacol. 2022, 922, 174886.
Crossref Google Scholar
[11]

Zhang, F.; Yin, Y. T.; Xu, T. T. Cinobufotalin injection combined with chemotherapy for the treatment of advanced NSCLC in China: A PRISMA-compliant meta-analysis of 29 randomized controlled trials. Medicine 2019, 98, e16969.
Crossref Google Scholar
[12]

Chen, T.; Li, D.; Fu, Y. L.; Hu, W. Screening of QHF formula for effective ingredients from Chinese herbs and its anti-hepatic cell cancer effect in combination with chemotherapy. Chin. Med. J. 2008, 121, 363–368.
Crossref Google Scholar
[13]

Li, X. W.; Chen, C. H.; Dai, Y.; Huang, C. Z.; Han, Q. R.; Jing, L. L.; Ma, Y.; Xu, Y. H.; Liu, Y. W.; Zhao, L. et al. Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of rapamycin/hypoxia-inducible factor 1α axis. Cancer Sci. 2019, 110, 1724–1734.
Crossref Google Scholar
[14]

Huang, F.; Ni, M.; Chalishazar, M. D.; Huffman, K. E.; Kim, J.; Cai, L.; Shi, X. L.; Cai, F.; Zacharias, L. G.; Ireland, A. S. et al. Inosine monophosphate dehydrogenase dependence in a subset of small cell lung cancers. Cell Metab. 2018, 28, 369–382.e5.
Crossref Google Scholar
[15]

Burrell, A. L.; Nie, C. K.; Said, M.; Simonet, J. C.; Fernández-Justel, D.; Johnson, M. C.; Quispe, J.; Buey, R. M.; Peterson, J. R.; Kollman, J. M. IMPDH1 retinal variants control filament architecture to tune allosteric regulation. Nat. Struct. Mol. Biol. 2022, 29, 47–58.
Crossref Google Scholar
[16]

Liu, X. L.; Madhankumar, A. B.; Miller, P. A.; Duck, K. A.; Hafenstein, S.; Rizk, E.; Slagle-Webb, B.; Sheehan, J. M.; Connor, J. R.; Yang, Q. X. MRI contrast agent for targeting glioma: Interleukin-13 labeled liposome encapsulating gadolinium-DTPA. Neuro-Oncol. 2016, 18, 691–699.
Crossref Google Scholar
[17]

Peng, C. Q.; Gao, X. F.; Xu, J.; Du, B. J.; Ning, X. H.; Tang, S. H.; Bachoo, R. M.; Yu, M. X.; Ge, W. P.; Zheng, J. Targeting orthotopic gliomas with renal-clearable luminescent gold nanoparticles. Nano Res. 2017, 10, 1366–1376.
Crossref Google Scholar
[18]

Zhao, Z.; Nelson, A. R.; Betsholtz, C.; Zlokovic, B. V. Establishment and dysfunction of the blood-brain barrier. Cell 2015, 163, 1064–1078.
Crossref Google Scholar
[19]

Steeg, P. S. The blood-tumour barrier in cancer biology and therapy. Nat. Rev. Clin. Oncol. 2021, 18, 696–714.
Crossref Google Scholar
[20]

Sarkaria, J. N.; Hu, L. S.; Parney, I. F.; Pafundi, D. H.; Brinkmann, D. H.; Laack, N. N.; Giannini, C.; Burns, T. C.; Kizilbash, S. H.; Laramy, J. K. et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncol. 2018, 20, 184–191.
Crossref Google Scholar
[21]

Alifieris, C.; Trafalis, D. T. Glioblastoma multiforme: Pathogenesis and treatment. Pharmacol. Ther. 2015, 152, 63–82.
Crossref Google Scholar
[22]

Van Tellingen, O.; Yetkin-Arik, B.; De Gooijer, M. C.; Wesseling, P.; Wurdinger, T.; De Vries, H. E. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist. Updat. 2015, 19, 1–12.
Crossref Google Scholar
[23]

Hu, C. M. J.; Fang, R. H.; Wang, K. C.; Luk, B. T.; Thamphiwatana, S.; Dehaini, D.; Nguyen, P.; Angsantikul, P.; Wen, C. H.; Kroll, A. V. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 2015, 526, 118–121.
Crossref Google Scholar
[24]

Zeng, Z. L.; Pu, K. Y. Improving cancer immunotherapy by cell membrane-camouflaged nanoparticles. Adv. Funct. Mater. 2020, 30, 2004397.
Crossref Google Scholar
[25]

Fan, Z. Y.; Li, P. Y.; Deng, J. J.; Bady, S. C.; Cheng, H. Cell membrane coating for reducing nanoparticle-induced inflammatory responses to scaffold constructs. Nano Res. 2018, 11, 5573–5583.
Crossref Google Scholar
[26]

Wang, C. X.; Wu, B.; Wu, Y. T.; Song, X. Y.; Zhang, S. S.; Liu, Z. H. Camouflaging nanoparticles with brain metastatic tumor cell membranes: a new strategy to traverse blood-brain barrier for imaging and therapy of brain tumors. Adv. Funct. Mater. 2020, 30, 1909369.
Crossref Google Scholar
[27]

Jia, Y. L.; Wang, X. B.; Hu, D. H.; Wang, P.; Liu, Q. H.; Zhang, X. J.; Jiang, J. Y.; Liu, X.; Sheng, Z. H.; Liu, B. et al. Phototheranostics: Active targeting of orthotopic glioma using biomimetic proteolipid nanoparticles. ACS Nano 2019, 13, 386–398.
Crossref Google Scholar
[28]

Zhou, C. Y.; Zhang, L.; Sun, T.; Zhang, Y.; Liu, Y. D.; Gong, M. F.; Xu, Z. S.; Du, M. M.; Liu, Y.; Liu, G. et al. Activatable NIR-II plasmonic nanotheranostics for efficient photoacoustic imaging and photothermal cancer therapy. Adv. Mater. 2021, 33, 2006532.
Crossref Google Scholar
[29]

Yin, J. H.; Pan, S. S.; Guo, X.; Gao, Y. S.; Zhu, D. Y.; Yang, Q. H.; Gao, J. J.; Zhang, C. Q.; Chen, Y. Nb2C MXene-functionalized scaffolds enables osteosarcoma phototherapy and angiogenesis/osteogenesis of bone defects. Nano-Micro Lett. 2021, 13, 30.
Crossref Google Scholar
[30]

Robinson, J. T.; Welsher, K.; Tabakman, S. M.; Sherlock, S. P.; Wang, H. L.; Luong, R.; Dai, H. J. High performance in vivo near-IR (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes. Nano Res. 2010, 3, 779–793.
Crossref Google Scholar
[31]

Wu, X. Z.; Suo, Y. K.; Shi, H.; Liu, R. Q.; Wu, F. X.; Wang, T. Z.; Ma, L. N.; Liu, H. G.; Cheng, Z. Deep-tissue photothermal therapy using laser illumination at NIR-IIa window. Nano-Micro Lett. 2020, 12, 38.
Crossref Google Scholar
[32]

Guo, B.; Sheng, Z. H.; Hu, D. H.; Liu, C. B.; Zheng, H. R.; Liu, B. Through scalp and skull NIR-II photothermal therapy of deep orthotopic brain tumors with precise photoacoustic imaging guidance. Adv. Mater. 2018, 30, 1802591.
Crossref Google Scholar
[33]

Li, S.; Zhang, Y.; Liu, X.; Tian, Y.; Cheng, Y.; Tang, L. G.; Lin, H. R. Smart NIR-II croconaine dye-peptide for enhanced photo-sonotheranostics of hepatocellular carcinoma. Theranostics 2022, 12, 76–86.
Crossref Google Scholar
[34]

He, T.; Jiang, C.; He, J.; Zhang, Y. F.; He, G.; Wu, J. Y. Z.; Lin, J.; Zhou, X.; Huang, P. Manganese-dioxide-coating-instructed plasmonic modulation of gold nanorods for activatable duplex-imaging-guided NIR-II photothermal-chemodynamic therapy. Adv. Mater. 2021, 33, 2008540.
Crossref Google Scholar
[35]

Shao, W.; Yang, C.; Li, F. Y.; Wu, J. H.; Wang, N.; Ding, Q.; Gao, J. Q.; Ling, D. S. Molecular design of conjugated small molecule nanoparticles for synergistically enhanced PTT/PDT. Nano-Micro Lett. 2020, 12, 147.
Crossref Google Scholar
[36]
Balakrishnan, P. B.; Ledezma, D. K.; Cano-Mejia, J.; Andricovich, J.; Palmer, E.; Patel, V. A.; Latham, P. S.; Yvon, E. S.; Villagra, A.; Fernandes, R. et al. CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. Nano Res. 2022, 15, 2300–2314.
[37]

Zeng, F. T.; Tang, L. G.; Zhang, Q. Y.; Shi, C. R.; Huang, Z. C.; Nijiati, S.; Chen, X. Y.; Zhou, Z. J. Coordinating the mechanisms of action of ferroptosis and the photothermal effect for cancer theranostics. Angew. Chem., Int. Ed. 2022, 61, e202112925.
Crossref Google Scholar
[38]

Liu, Z.; Wang, J. Q.; Qiu, K. Q.; Liao, X. X.; Rees, T. W.; Ji, L. N.; Chao, H. Fabrication of red blood cell membrane-camouflaged Cu2−xSe nanoparticles for phototherapy in the second near-infrared window. Chem. Commun. 2019, 55, 6523–6526.
Crossref Google Scholar
[39]

Wan, H.; Zhang, Y.; Liu, Z. Y.; Xu, G. J.; Huang, G.; Ji, Y. S.; Xiong, Z. C.; Zhang, Q. Q.; Dong, J.; Zhang, W. B. et al. Facile fabrication of a near-infrared responsive nanocarrier for spatiotemporally controlled chemo-photothermal synergistic cancer therapy. Nanoscale 2014, 6, 8743–8753.
Crossref Google Scholar
[40]

You, Q.; Sun, Q.; Wang, J. P.; Tan, X. X.; Pang, X. J.; Liu, L.; Yu, M.; Tan, F. P.; Li, N. A single-light triggered and dual-imaging guided multifunctional platform for combined photothermal and photodynamic therapy based on TD-controlled and ICG-loaded CuS@mSiO. Nanoscale 2017, 9, 3784–3796.
Crossref Google Scholar
[41]

Chin, R. M.; Fu, X. D.; Pai, M. Y.; Vergnes, L.; Hwang, H.; Deng, G.; Diep, S.; Lomenick, B.; Meli, V. S.; Monsalve, G. C. et al. The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature 2014, 510, 397–401.
Crossref Google Scholar
[42]

Lomenick, B.; Hao, R.; Jonai, N.; Chin, R. M.; Aghajan, M.; Warburton, S.; Wang, J. N.; Wu, R. P.; Gomez, F.; Loo, J. A. et al. Target identification using drug affinity responsive target stability (DARTS). Proc. Natl. Acad. Sci. USA 2009, 106, 21984–21989.
Crossref Google Scholar
[43]

Jafari, R.; Almqvist, H.; Axelsson, H.; Ignatushchenko, M.; Lundbäck, T.; Nordlund, P.; Molina, D. M. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 2014, 9, 2100–2122.
Crossref Google Scholar
[44]

Liu, Z.; Chan, L.; Chen, L. Y.; Bai, Y.; Chen, T. F. Facile fabrication of near-infrared-responsive and chitosan-functionalized Cu2Se nanoparticles for cancer photothermal therapy. Chem. Asian J. 2016, 11, 3032–3039.
Crossref Google Scholar
[45]

Li, Q.; Sun, L. H.; Hou, M. M.; Chen, Q. B.; Yang, R. H.; Zhang, L.; Xu, Z. G.; Kang, Y. J.; Xue, P. Phase-change material packaged within hollow copper sulfide nanoparticles carrying doxorubicin and chlorin e6 for fluorescence-guided trimodal therapy of cancer. ACS Appl. Mater. Interfaces 2019, 11, 417–429.
Crossref Google Scholar
[46]

Bicker, J.; Alves, G.; Fortuna, A.; Falcão, A. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: A review. Eur. J. Pharm. Biopharm. 2014, 87, 409–432.
Crossref Google Scholar
[47]

Hanafy, A. S.; Dietrich, D.; Fricker, G.; Lamprecht, A. Blood-brain barrier models: Rationale for selection. Adv. Drug Deliv. Rev. 2021, 176, 113859.
Crossref Google Scholar
Nano Research
Volume 16 Issue 8,
August 2023
Pages 11164-11175
DOI: 10.1007/s12274-023-5807-7
Cite this article:
Song Z, Zhao L, Fang W, et al. Glioma cell membrane camouflaged cinobufotalin delivery system for combinatorial orthotopic glioblastoma therapy. Nano Research, 2023, 16(8): 11164-11175. https://doi.org/10.1007/s12274-023-5807-7
Topics:
Drug deliveryTumors

1028

Views

6

Crossref

8

Web of Science

8

Scopus

0

CSCD

Altmetrics
Received: 02 February 2023
Revised: 29 April 2023
Accepted: 05 May 2023
Published: 09 June 2023
© Tsinghua University Press 2023
Return